Despite what the name suggests, Polycystic Ovary Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PCOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PCOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PCOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PCOS so challenging—and why understanding your unique experience matters.
So, how can the PCOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PCOS—and make progress.
Here’s what you’ll find at PCOSA:
✅ Reliable, science-backed information about what PCOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PCOS patients
🙋♀️ Advocacy to make sure PCOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PCOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
Per- and polyfluoroalkyl substances (PFAS) have been previously associated with polycystic ovary syndrome (PCOS). However, the health effects of emerging PFAS alternatives on PCOS remain unclear. This study aims to examine the associations between exposure to emerging PFAS alternatives and the odds of PCOS, while also exploring the combined effects of PFAS mixture exposure. From 2019 to 2024, we conducted a case-control study in Jiangsu Province, China, including 94 women diagnosed with PCOS and...
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Yongmei Li, Suya Kang, Hui Xu, Yue Zhang, Hui Li, Jun Yan, Liping Zhou,
Polycystic ovary syndrome (PCOS) is characterized by a constellation of symptoms, including menstrual cycle irregularities, hyperandrogenism, and polycystic ovarian morphology. Despite extensive research efforts, a thorough understanding of the underlying pathophysiology and effective treatment options for PCOS remain elusive. In this study, ovarian tissues from dehydroepiandrosterone (DHEA)-induced PCOS mice and control mice underwent mRNA sequencing. Through a comprehensive bioinformatics...
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Mingxing Sui, Shuying Wu, Qingqing Song, Siyao Chen, Yingli Lu,
CONCLUSION: TJZL exerts beneficial therapeutic effects on PCOS in both clinical and laboratory studies. TJZL improves PCOS by regulating multiple endogenous metabolites and correcting abnormal steroid synthesis and arachidonic acid metabolism in the ovaries. Our research provides a promising therapeutic agent for PCOS patients.
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Huili Zheng, Tingting Shang, Wenting Gao, Luyao Zhou, Peijuan Wang, Qingling Ren, Hongjuan Yu, Qun Zhan, Chunyun Liang, Qiuyan Shi, Yachun Shu, Sheng Guo, Shulan Su, Yue Zhu, Jin-Ao Duan,
Endocrine disrupting chemicals (EDCs) are widespread environmental contaminants that may contribute to the development of metabolic diseases. However, their causal roles and biological mechanisms remain unclear. This study aimed to investigate the associations between EDC exposure and metabolic disorders by integrating epidemiological and genetic approaches. A pooled analysis of 53 observational studies, comprising 109394 participants, demonstrated that EDC exposure significantly increased the...
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Lang Wang, Xiaoyu Liu, Chenyu Xiang, Xinpeng Shu, Xurui Liu, Junnan Zhao, Siqi Li, Rongbin Xu, Bo Chen, Bing Kang, Dong Peng,
Nuclear androgen receptor (AR) dysregulation characterizes polycystic ovary syndrome (PCOS) pathophysiology and contributes to mitochondrial dysfunction-related adverse pregnancy outcomes. However, ARs also localize to mitochondria in many cell types, and mitochondrial dysfunction is implicated in the underlying pathogenesis of PCOS. In this study, human endometrial decidual basalis tissues and rat gravid uterine tissues were collected, and subcellular fractionation, Western blot, quantitative...
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Yuehui Zhang, Min Hu, Linus R Shao, Lingjing Lu, Jing Han, Tingting Guo, Meng Jiang, Yao Wu, Han Han, Peng Cui, Mats Brännström, Amanda Nancy Sferruzzi-Perri, Håkan Billig,
CONCLUSION: The risk factors and pregnancy outcomes associated with GDM in twin pregnancies vary by chorionicity.
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Shuai Huang, Xiaoyan Li, Jing Zheng, Gao Qiu, Ping Luo, Lu Mao, Hongbo Qi,
No abstract
Published on: Fri, 16 Jan 2026 06:00:00 -0500
Authors: Vijayakumar K, Rajesh Karekar, Pranavi Sharma,
CONCLUSION: Non-obese women with PCOS had a higher prevalence of fatty liver, with minor differences in metabolic parameters, and BMI partly mediated these associations.
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Fateme Amiri, Homeira Rashidi, Leila Moradi, Seyedbahman Ghderian, Reyhanesadat Taghavi,
Background Menstrual disorders such as dysmenorrhea, menorrhagia, oligomenorrhea, and premenstrual syndrome are believed to be the most common yet under-recognized causes of morbidity in adolescent girls. Many adolescents around the world experience menstrual dysfunction, and in India, cultural stigma, poor awareness, and nutritional imbalance are believed to exacerbate the burden. Despite national initiatives focusing on menstrual hygiene and anemia prevention, only a few studies in India have...
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Pragya Prem, Veena S R, Meena T S, Revathy T G,
No abstract
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Min Xing, Jing Li, Xiaolan Wu, Ruyi Zhang, Lan Li, Huiping Liu,
CONCLUSIONS: Valproate exposure was associated with an increased risk of PCOS. The risk was especially pronounced during current and cumulative exposure, whereas overall cumulative exposure suggested increased risk at higher thresholds. These findings suggest that PCOS risk may be driven by acute pharmacological effects, although long-term cumulative use may also contribute. The results reinforce recommendations to avoid valproate in women of reproductive age when possible.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Maria Holmskov, Jakob Christensen, Mie Frederiksen Larsen, Ann-Eva Christiansen, René Ernst Nielsen,
CONCLUSION: In a 12-week cross-over feasibility study, TRE was a safe and feasible intervention. Recruitment was challenging and with limited numbers, the TRE group showed a decrease in HbA1c and anthropometric indices compared to the 'ad libitum' group.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Ruairí Floyd, Adam Dyer, James Gibney, Fatimah Alawami, Lisa Owens, Niamh Phelan, Ana Rakovac, Patrick Swan, Carel W LeRoux, Lucy Ann Behan, Sinead N Duggan,
Polycystic ovary syndrome (PCOS) accelerates ovarian follicular depletion through atresia. This study investigated the therapeutic potential of aqueous (AE) and hydroethanolic (HEE) extracts of Cymbopogon citratus in mitigating PCOS-induced ovarian damage (specifically ferroptosis, apoptosis, and oxidative stress) in a rat model of PCOS. PCOS was induced by oral administration of letrozole (1 mg/kg/day for 21 days), followed by treatment with AE or HEE (100, 200, or 400 mg/kg/day for 20 days)...
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Vanis Slauvers Akago, Marie Alfrede Mvondo, Sefirin Djiogue, Stephen Lacmata Tamekou, Nina-Sonia Messongue Mbollo, Josue Jobin Biba, Agatha Yelah Ntumnyuy, Lylie Gisèle Atsafack Mboudem, Perpetue Atsama Mbede, Christophe Mezui, Hélène Carole Edima-Durand, Jules-Roger Kuiate, Dieudonné Njamen,
CONCLUSION: This study showed that the combined effect of Nigella sativa and Salvia officinalis was better able to treat PCOS and may replace Metformin to improve PCOS-induced abnormalities.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Hiba Faour, Samah Hachem, Miriam Al Battal, Jamilah Borjac,
CONCLUSIONS: Naringenin may ameliorate PCOS by downregulating hypothalamic Kiss1 and Cgrp gene expression in rats. These results suggest a novel mechanism of naringenin's action and highlight its potential for clinical application.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Manizheh Habibi, Fariba Mahmoudi, Khadijeh Haghighat, Homayoun Khazali,